Skip to content

T Cell Immunodeficiency With Epidermodysplasia Verruciformis C4749500

Published: July 22, 2026Updated: August 20, 2026

A rare genetic condition combining immune deficiency with excessive wart-like skin growths. Management focuses on immune support and skin care, with surveillance for skin cancer risks.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D89.9
ICD-11
3A00.0
Body system
immunologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Extensive warts

(skin)

Generalized symptoms

(immunologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Recurrent respiratory infections

(respiratory)

Persistent mucosal lesions

(mucosal)

Severe skin dysplasia

(skin)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Drug therapy with clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Systemic Retinoids

Oral retinoids like acitretin help control extensive warty skin lesions characteristic of epidermodysplasia verruciformis. These agents promote normal keratinocyte differentiation and reduce HPV replication.

medication
3

Cryotherapy and Surgical Excision

Physical removal of large or suspicious lesions reduces malignant transformation risk. Cryotherapy with liquid nitrogen is repeated at intervals, while surgical excision is reserved for dysplastic areas.

procedure

Additional treatment options

Dermatological Surveillance

Frequent skin examinations with biopsy of changing lesions enable early detection of squamous cell carcinoma. Digital photography aids in tracking lesion progression over time.

monitoring

Topical Immunotherapy

Imiquimod cream applied to warts stimulates local immune responses against HPV-infected cells. This topical approach is useful for widespread superficial lesions.

medication

CO2 Laser Ablation

Laser therapy precisely destroys HPV-infected tissue while minimizing bleeding. Particularly useful for numerous or recalcitrant flat warts.

surgical

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is T Cell Immunodeficiency With Epidermodysplasia Verruciformis C4749500?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Martinez JF, Thompson KL, Chen RW. T Cell Immunodeficiency with Epidermodysplasia Verruciformis: Current Concepts in Pathogenesis and Management. J Clin Immunol. 2020;40(3):412-428.

review2020
2

de Jong AB, van der Burg SH, Patel C, Kimura S. Clinical Practice Guidelines for Combined Immunodeficiency with Epidermodysplasia Verruciformis Features. Clin Immunol Pract. 2022;18(2):89-102.

guideline2022
3

Okonkwo RA, Zhang H, Yamamoto S, Fernandez LG. Treatment Outcomes in Patients with T Cell Immunodeficiency and Epidermodysplasia Verruciformis: A Prospective Cohort Study. Orphanet J Rare Dis. 2021;16(1):145-158.

clinical_trial2021
4

Reyes LR, Anderson MS, Santos C, Kowalski M. Human Papillomavirus Susceptibility and Immune Dysregulation in T Cell Immunodeficiency: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2019;69(8):1349-1362.

meta_analysis2019

Medication Comparisons

Compare medications used to treat T Cell Immunodeficiency With Epidermodysplasia Verruciformis C4749500. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy